Diabetes news 2006

2006-06-17 Data Presented at American Diabetes Association Annual Meeting Suggest Testosterone Levels Correlate with Insulin Resistance and Insulin Sensitivity in Type 2 Diabetes Patients

MALVERN, Pa /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) , a specialty pharmaceutical company, announced that new findings presented today at the American Diabetes Associations 66th Annual Scientific Sessions suggest that abnormally low testosterone levels may be linked to progression of Type 2 diabetes. The data are obtained from patient screening for a prospective study and include 568 men with Type 2 diabetes. Researchers found a general increase in insulin resistance in patients with Type 2 diabetes who have low total testosterone levels, compared to Type 2 diabetes patients with normal total testosterone levels. Recent studies have highlighted the potential importance of androgen concentrations in relation to insulin sensitivity. This latest cohort analysis provides evidence of the need for

www.drugnewswire.com

Data Presented at American Diabetes Association Annual Meeting Suggest Testosterone Levels Correlate with Insulin Resistance and Insulin Sensitivity in Type 2 Diabetes Patients - Data Presented at American Diabetes Association Annual Meeting Suggest Testosterone Levels Correlate with Insulin Resistance and Insulin Sensitivity in Type 2 Diabetes Patients

2006-10-03 VeraLight Receives USPTO Notice of Allowance Covering Dermal Fluorescence Technology to Detect Diabetes: Financial News - Yahoo. Finance

Results from recently announced scientific studies have shown VeraLights diabetes screening system -- code-named "Scout" -- was able to significantly outperform the FPG test and the A1C test for identifying diabetes and pre- diabetes in individuals with one or more known risk factors for the disease. Against the results of a two-hour oral glucose tolerance test used for validation, a prototype of the device was able to identify 29 pct. more patients than the FPG test and 17 pct. more patients than the A1C test. Both the FPG and A1C are blood tests used to screen patients at risk for diabetes.

biz.yahoo.com

VeraLight Receives USPTO Notice of Allowance Covering Dermal Fluorescence Technology to Detect Diabetes. - ALBUQUERQUE, N. M. , Oct. 3 /PRNewswire/ -- VeraLight, Inc. , a privately held medical device company, today announced that it has received a Notice of Allowance from the U. S.

2006-08-21 Multi-Generational Survey Uncovers Behavior Changes as Greatest Challenge in Diabetes Management: Younger Generations Lagging Behind: Financial News - Yahoo. Finance

Younger Generation Lagging Behind in Healthy Behaviors: Younger generations continue to lag behind older generations in incorporating more fruits and vegetables into their diet (Gen X/Y: 62 percent, BB: 70 percent and 60+: 77 percent); of people with diabetes, 85 percent of respondents over the age of 60 reported taking a hemoglobin A1C test every three to six months (a blood test that determines average blood glucose control) compared to their younger counterparts Gen X/Y (62 percent) and baby boomers (77 percent); and 55 percent of the youngest respondents reported checking blood glucose regularly versus 82 percent of seniors. Complications Hitting Hard: Seventy-five percent of the younger generations reported complications associated with the disease including high blood pressure,

biz.yahoo.com

Multi-Generational Survey Uncovers Behavior Changes as Greatest Challenge in Diabetes Management: Younger Generations Lagging Behind. - PRINCETON, N. J /PRNewswire/ -- A groundbreaking national survey released today looking at three generations of diabetes sufferers revealed that adults ages 18-40, who are at risk for or living with type 2 diabetes, are lagging behind their parents and

2006-08-01 VeraLight Raises usd. 17. 5 Million in Series B Financing to Commercialize Non-Invasive Diabetes Screening Device: Financial News - Yahoo. Finance

Results from a clinical study presented recently at the annual scientific sessions of the American Diabetes Association showed a prototype of the VeraLight Scout was able to identify 20 percent more pre-diabetes and type-2 diabetes patients than the standard fasting glucose test. Scout utilizes proprietary fluorescence spectroscopic technology, does not require patient fasting or a blood draw, and provides results in about 60 seconds. The subject places the palm side of the forearm onto the portable table-top system. Scout shines various wavelengths of light on the skin to stimulate fluorescence that is measured by the machine to provide an indication of diabetes risk based on the presence of biological markers called "advanced glycation endproducts," or AGEs, found in skin. Studies have shown that AGEs correlate well with diabetes

biz.yahoo.com

VeraLight Raises usd. 17. 5 Million in Series B Financing to Commercialize Non-Invasive Diabetes Screening Device. - ALBUQUERQUE, N. M. , Aug. 1 /PRNewswire/ -- VeraLight, Inc. , a privately held medical device company, today announced the successful completion of a usd. 17. 5 million Series B financing that will be used to complete development, testing, and introduction of the VeraLight Scout diabetes

2006-03-27 You or Someone You Love Could Have Diabetes and Not Know It; Rite Aid and the American Diabetes Association Sound the Alert for Diabetes Awareness Nachrichten Aktienkurs

In addition to supporting the mission of the ADA, Rite Aid helpedraise almost usd. 1 million to benefit the ADA through its "DiabetesStars" program. Rite Aid also offers regular "Diabetes Days" in storeswhere individuals can take the Risk Test, receive advice frompharmacists on medications and side effects, and receive exercise andnutrition information. Information and resources on diabetes can befound at , where visitors can receivecustomized diabetes information based on their current stage ofdiabetes or as a care giver. Rite Aid also sponsors a page on theADAs Web site ( ) called "Ask the Pharmacist. " Thisfeature allows visitors to submit questions about diabetes managementand receive guidance from a Rite Aid pharmacist.

finanzen.net

B. rse von finanzen. net: t. glich ca. 300 Aktien-Nachrichten, Marktberichte, Aktienberichte, Analysen, Aktienanalysen und B. rsenberichte, Kursabfragen zu Aktien, Fonds, Optionsscheinen, Zertifikaten - B. rse Ad-hoc Marktberichte Pressemitteilungen B. rsenberichte Wirtschaft

2006-09-17 Eighth Annual Novartis Prize In Diabetes Award Recipients Announced

In the recent past diabetes organisations thought that glucose tolerance tests were not usually necessary in order to diagnose diabetes. In one of the earliest examinations of the new category of impaired fasting glucose, Professor Jonathan Shaw, Deputy Director, International Diabetes Institute, Melbourne, Australia, questioned the validity of the lower threshold of the category, and suggested that a lower value would be more consistent with available data1. In what was to become a key area of international dispute over later years, Dr. Shaw analysed the impact of the ADAs recommendation that the oral glucose tolerance test was not usually necessary for the diagnosis of diabetes. In a key paper, Professor Shaw demonstrated that the post-challenge glucose value was a stronger predictor of mortality than was the fasting glucose, and

www.medicalnewstoday.com

Four recipients of the eighth annual Novartis Prize in Diabetes were honoured for their significant achievements in researching diabetes risk and management during the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen to 17, 2006 - Diabetes news medical news health news medical headlines healthcare news health articles medicine articles welfare living

2006-09-15 PharmaLive: Novartis Announces Recipients of Eighth Annual Novartis Prize in Diabetes Award

In the recent past diabetes organisations thought that glucose tolerance tests were not usually necessary in order to diagnose diabetes. In one of the earliest examinations of the new category of impaired fasting glucose, Professor Jonathan Shaw, Deputy Director, International Diabetes Institute, Melbourne, Australia, questioned the validity of the lower threshold of the category, and suggested that a lower value would be more consistent with available data1. In what was to become a key area of international dispute over later years, Dr. Shaw analysed the impact of the ADA and rsquo;s recommendation that the oral glucose tolerance test was not usually necessary for the diagnosis of diabetes. In a key paper, Professor Shaw demonstrated that the post-challenge glucose value was a stronger predictor of mortality than was the fasting

www.medadnews.com

2006-07-10 Alteon Research Collaborator Receives Funding from Juvenile Diabetes Research Foundation for Diabetic Complications Clinical Study Investigating Alagebrium and Renal Function: Financial News -

A Phase 2 protocol for the clinical study has been developed. The randomized, double-blind, placebo-controlled study will test alagebrium in 80 patients with type 1 diabetes between the ages of 18-65 who are in the early stages of kidney disease. There will be an 8-week single-blind, run-in period during which placebo and an ACE inhibitor, standard background therapy for this patient population, will be administered to all patients. This will be followed by 24 weeks of double-blind treatment with either placebo or alagebrium in combination with an ACE inhibitor. Changes in albumin excretion rate will be the primary endpoint of the study. The study, which is expected to be initiated in the fourth quarter of 2006, will be conducted at three sites in Australia and one in Denmark. Notable nephrologist Hans-Henrik Parving, M. D. ,

biz.yahoo.com

Alteon Research Collaborator Receives Funding from Juvenile Diabetes Research Foundation for Diabetic Complications Clinical Study Investigating Alagebrium and Renal Function. - PARSIPPANY, N. J /PRNewswire-FirstCall/ -- Alteon Inc. (Amex: ALT - News) announced today that one of its collaborators, Mark Cooper, M. D. , Ph. D. , Professor, the Baker Heart Research Institute, Melbourne,

2006-07-07 Bayer Acquires Metrika Inc.

Bayer HealthCare Diabetes Care is one of the largest self-test diagnostic businesses in the world, supporting customers in 100 countries. Since the introduction of Clinitest(R) reagent tablets in 1941, Bayer has led the way in diabetes care product innovation. The company changed the face of diabetes care in 1969 when it introduced the first portable blood glucose meter and test strips. Bayer HealthCare further innovated diabetes self-management by being the first company to introduce a suite of blood glucose monitors that do not require coding. The BREEZE(R), CONTOUR(R), and DEX(R) 2 blood glucose monitoring systems offer people with diabetes an unparalleled choice in diabetes management systems. Recently, the Canadian and American Arthritis Foundations granted ease-of use designation to the Breeze meter, representing

www.medicalnewstoday.com

Bayer Diabetes Care, a division of Bayer HealthCare LLC and a member of the Bayer Group (NYSE: BAY), announced today that it has acquired Metrika Inc - Diabetes news medical news health news medical headlines healthcare news health articles medicine articles welfare living

2006-04-20 MannKind Corporation :: Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss

Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss

According to the United States Centers for Disease Control, or CDC, as of 2005, approximately 20. 8 million people in the United States, or 7 pct. of the population, suffered from diabetes. The CDC estimated that 14. 6 million cases of diabetes were diagnosed and under treatment and that 1. 5 million new cases would be diagnosed in 2005. The CDC reported that diabetes was the sixth leading cause of death listed on death certificates in 2002, but that diabetes was likely to be underreported as a cause of death. Overall, the CDC found that the risk of death among people with diabetes is about twice that of people without diabetes of similar age. The American Diabetes Association estimated that, in 2002, the total cost of diabetes in the United States was usd. 132 billion. This amount includes usd. 12 billion of direct costs for drug treatment,

sev.prnewswire.com

MannKind Corporation (NASDAQ: MNKD) today announced results from a Phase 2 clinical study of inhaled insulin in people with Type 1 diabetes. The study was designed to evaluate whether inhaled insulin delivered using the MannKind Technosphere(R) Insulin System showed similar safety and efficacy at controlling blood sugar based on dosing regimens commonly used in the every day management of